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Abstract: Extramedullary hematopoiesis (EH) is defined as hematopoiesis occurring in organs 
outside of the bone marrow; it occurs in diverse conditions, including fetal development, normal 
immune responses, and pathological circumstances. During fetal development, before formation 
of mature marrow, EH occurs in the yolk sac, fetal liver, and spleen. EH also occurs during 
active immune responses to pathogens. Most frequently, this response occurs in the spleen and 
liver for the production of antigen-presenting cells and phagocytes. EH also occurs when the 
marrow becomes inhabitable for stem and progenitor cells in certain pathological conditions, 
including myelofibrosis, where marrow cells are replaced with collagenous connective tis-
sue fibers. Thus, EH occurs either actively or passively in response to diverse changes in the 
hematopoietic environment. This article reviews the key features and regulators of the major 
types of EH.
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Introduction
Extramedullary hematopoiesis (EH) refers to the hematopoiesis that occurs in organs 
other than bone marrow. A classic example of EH is the increased ectopic erythropoiesis 
in a liver or spleen in hypoxia due to increased erythropoietin production.1 EH can be 
further classified into active or passive categories. Normal hematopoiesis, which occurs 
in the fetal yolk sac, liver, and spleen, is an example of active EH; it is programmed 
as an essential process for routine fetal development. Another example of active 
EH is that which occurs in the spleen and liver during immune responses following 
infection. By contrast, EH also occurs as a result of failed marrow hematopoiesis in 
peripheral organs such as the liver and spleen and this is considered a passive form of 
EH. Both active and passive EH produce blood cells such as antigen-presenting cells, 
granulocytes, NK cells, red blood cells, and/or platelets for the growth or survival of 
the host. Inadequate EH leads to insufficient production or maturation of blood cells, 
while excessive EH leads to inflammatory diseases (Figure 1). This article will review 
the key aspects of major types of EH.
Factors required for hematopoiesis
Hematopoiesis is a complex process regulated by multiple factors. Hematopoiesis 
occurs in specialized tissue sites (eg, “hematopoietic niches”) conducive for the 
maintenance and differentiation of stem and progenitor cells. For example, hemato-
poietic stem cells, which are quiescent and self-renewing, are present in the marrow Journal of Blood Medicine 2010:1 14
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stem cell niche, which is low in oxygen and favorable to 
maintaining their identity as stem cells.2 The marrow stem 
cell niche is composed of various cells and their products 
which positively and negatively regulate the process.3,4 
Key regulatory cells include osteoblasts, CXC chemokine 
ligand 12 (CXCL12)-expressing reticular cells, and vascular 
endothelium cells.5–8 Moreover, signals from the sympathetic 
nervous system and osteoclasts regulate the hematopoietic 
stem cell egress from the bone marrow through regulation 
of a critical stem cell homing and retention factor termed 
CXCL12.9,10 The requirement of a specialized niche is a 
limiting factor for EH in the periphery. As a consequence, 
EH is usually limited in the periphery at specific times and 
under certain conditions.
A number of molecular pathways including Wnt, calcium-
sensing receptors, angiopoietin 1, Tie-2, and extracellular 
matrix components are involved in the process to finely 
control the stem cell niche.6,7,11–13 Although incompletely 
understood, these pathways are thought to be involved not 
only in the maintenance of the stem cell niche but also in 
renewal and differentiation of hematopoietic stem cells 
within the niche. Various cells produce hematopoietic cyto-
kines such as stem cell factor (SCF), notch ligands, bone 
morphogenic proteins, transforming growth factor β, throm-
bopoietin (TPO), fibroblast growth factors, and insulin-like 
growth factor 2, which maintain and regulate the primitive 
hematopoietic stem cells.14 Other cytokines, such as granu-
locyte colony stimulating factor (G-CSF), interleukin-3 
(IL-3), IL-7, erythropoietin (EPO), granulocyte macrophage 
(GM)-CSF, and macrophage (M)-CSF, play important roles 
in the differentiation of hematopoietic stem and progenitor 
cells to committed cell lineages.15
In addition to the aforementioned cells and factors, 
hematopoiesis can be regulated by a number of other means, 
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Figure 1 Major forms of extramedullary hematopoiesis. extramedullary hematopoiesis occurs early in fetal development and also plays important roles in adult life. Hematopoiesis 
occurs in the fetal liver and spleen. Hematopoietic stem and progenitor cells in the fetal liver migrate to the bone marrow and the marrow becomes the major hematopoietic 
site after birth. The hematopoietic stem and progenitor cells in the bone marrow emigrate to the periphery such as the liver and spleen. Upon infection and resultant immune 
responses, various hematopoietic factors including TLr ligands and cytokines promote extramedullary hematopoiesis in the liver and spleen. A major role of this extramedullary 
hematopoiesis is to produce functionally mature antigen-presenting cells and phagocytes. excessive and prolonged extramedullary hematopoiesis in the periphery occurs in 
the presence of autoimmune diseases and chronic infection. in these situations, extramedullary hematopoiesis is harmful for the host. when malignant disease such as primary 
myelofibrosis occurs, the marrow becomes unsuitable to support hematopoiesis and extramedullary hematopoiesis is greatly increased.Journal of Blood Medicine 2010:1 15
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such as Toll-like receptor ligands, metabolic/physiological 
products, various inflammatory mediators, and hormones.2,16–18 
Many of the cytokines produced in inflammation act as 
myelopoietic factors,19 certain Toll-like receptor ligands 
promote myelopoiesis,20 and hypoxia is a well known inducer 
of erythropoiesis.21 Also, parathyroid hormone (PTH) and 
the insulin-like growth factors (IGF) control the hematopoi-
etic stem cell niche; PTH can increase the number of bone 
marrow stem and progenitor cells and IGF can regulate the 
survival and expansion of hematopoietic stem and progeni-
tor cells.18 Many of the cell types produced in the marrow, 
such as monocytes and B cells, require further maturation 
in the periphery to become fully functional immune cells. 
Monocytes will migrate into various tissue sites to become 
macrophages or dendritic cells and B cells must be activated 
in the periphery to become memory and plasma cells. Naïve 
T cells are made in the thymus from progenitors that origi-
nated in the marrow and they undergo further differentiation 
in response to antigens proffered by antigen-presenting cells. 
Thus, the term “extramedullary hematopoiesis” refers to a 
broad range of hematopoietic activities from the early stages 
of lineage commitment to late stages of hematopoietic cell 
maturation.
Early EH during fetal development
Bone marrow becomes functional as a site of hematopoiesis 
in the fetus from 4–5 months in human pregnancy. In mice, 
the marrow hematopoiesis is delayed somewhat and becomes 
active following birth. The developing fetus needs hemato-
poietic cells for the supply of oxygen and other less obvi-
ous reasons. Therefore, nonmarrow tissues serve as sites of 
hematopoiesis before the bone marrow takes over the role 
as the major hematopoietic site. In early embryo, the yolk 
sac serves as the primary site of hematopoiesis.22,23 During 
mid-gestation, yolk sac cells colonize the umbilical cord, the 
aorta-gonad-mesonephros (AGM) region, and subsequently 
the embryonic liver. The yolk sac produces hematopoietic 
stem cells and red blood cells initially, but later produces 
myeloid cells as well.24 In this regard, the yolk sac is an 
important place, harboring primitive erythroblasts and essen-
tially all definitive HPC. Later in embryonic development, 
some of these cells seed the fetal liver.25 As mentioned, the 
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Figure 2 Regulation of extramedullary hematopoiesis during immune responses.    An example of the regulatory mechanism for EH is illustrated. In the spleen, EH, exemplified by 
maturation of myeloid progenitors into mature neutrophils and dendritic cells, constitutively occurs at low levels. During infection and inflammation, this process is greatly increased 
due to activated  T cells producing hematopoietic cytokines such as GM-CSF and iL-3. An important negative regulator of eH is the FoxP3+ regulatory  T cell. FoxP3+ regulatory  T cells 
suppress the differentiation of naïve  T cells into hematopoietic cytokine-producing effector  T cells in response to antigens imparted by antigen-presenting cells. Since it is known that 
FoxP3+ regulatory T cells can suppress more than T cells, there is the possibility that FoxP3+ regulatory T cells suppress eH via the regulation of additional target cell types.Journal of Blood Medicine 2010:1 16
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next hematopoietic tissue site after the yolk sac is AGM and 
later, the fetal liver becomes a major hematopoietic site. 
Ultimately, the bone marrow becomes the predominant site 
of hematopoiesis. Following birth, the number of colony-
forming hematopoietic progenitors in the spleen increases, 
peaking at two weeks of age in mice.26 In fact, the spleen 
remains a hematopoietic organ in mice throughout their lives, 
albeit at low levels.
It is thought that the liver ceases to act as a site of hema-
topoiesis after birth. However, the liver maintains hemato-
poietic stem cells, erythropoiesis, and myelopoiesis at low 
levels during adult life.27 Moreover, the liver is considered 
a maturation site for unconventional T cells including NKT 
cells, CD8αα T cells, CD4-CD8- double-negative T cells, 
and γδ T cells.
Induced EH occurs during infection 
and immune responses
Following birth in mammals and rodents, extramedullary 
hematopoiesis occurs when immune responses occur in the 
periphery (Figure 1). The liver and spleen are the main sites 
of extramedullary hematopoiesis. Other organs such as the 
lungs, kidney, and the peritoneal cavity can also become the 
sites of hematopoiesis when in diseased states.
The increased extramedullary hematopoiesis in the 
spleen and liver of FAS (CD95)-deficient mice provides a 
useful insight into the cause of EH.28 In FAS-deficient mice, 
hematopoietic cells are resistant to apoptosis, allowing these 
cells to grow in organs which are normally not conducive 
for growth and differentiation of hematopoietic stem and 
progenitor cells. Also, immune cells are greatly expanded 
in these mice, producing large volumes of cytokines that 
can feed the growth of hematopoietic progenitor cells in the 
periphery. Another example of induced EH is the increased 
myelopoiesis found in many organs of FoxP3-null scurfy 
mice. Scurfy mice display increased CD11b+ myeloid cells 
in the spleen and the liver, which is consistent with increased 
expression of GM-CSF and IL-3.29 In scurfy mice, T cells 
producing GM-CSF and IL-3 are overly activated in the 
absence of FoxP3+ T cells, driving excessive EH in the spleen 
and liver. By contrast, the transfer of functional FoxP3+ 
T cells into newborn scurfy mice completely suppresses 
EH and scurfy-related inflammatory disease.30 An important 
function of the FoxP3+ T cells is to suppress the differentia-
tion of naïve T cells into hematopoietic cytokine-producing T 
effector T cells (Figure 2).30 FoxP3+ T cells function mainly 
in the T-ell zone of the spleen rather than in the red pulps 
where EH occurs.
NK cells appear to play a negative role in the regulation of 
EH in the spleen. Depletion of NK cells with the anti-NK1.1 
antibody in postnatal mice increased myeloid progenitor 
cells by 3–10 times in the spleen.31 This study, however, 
did not determine if the increase was the outcome of cell 
mobilization from the bone marrow or the product of the 
EH in the spleen. In vitro, NK cells can conversely decrease 
the numbers of progenitor cells.32,33 While the mechanism 
remains to be determined, NK cells could perhaps regulate 
the hematopoiesis with soluble inhibitory factors or through 
their cell-killing activity.
Toxic shock syndrome toxin-1 (TSST-1) is a superantigen 
produced by most Staphylococcus aureus strains. Supe-
rantigens can conjugate the MHC II molecules of antigen-
presenting cells and certain β chains of T cell receptors for 
polyclonal activation of T cells. T cells are a good source of 
hematopoietic factors such as GM-CSF, IL-3 and oncostatin 
M.30,34,35 In this regard, TSST-1 can induce the production of 
hemopoietic factors.36 Staphylococcus enterotoxin B (SEB) 
is another superantigen produced by Staphylococcus aureus. 
SEB can activate naïve T cells and induce their differentiation 
into effector T cells that produce GM-CSF and IL-3.30
Microbial components such as TLR ligands can affect 
hematopoiesis in both the marrow and spleen. TLR ligands 
such as lipopolysaccharides (LPS, a TLR2 ligand) and 
Pam3CSK4 (a TLR4 ligand) can directly activate hematopoi-
etic progenitor cells through their receptors.37 Consequently, 
differentiation of progenitors into myeloid cells, such as 
macrophages and dendritic cells, is greatly enhanced in vitro 
while myeloid cells in marrow and spleen are increased 
following the injection of LPS in vivo. Interestingly, TLR 
ligands can turn even lymphoid progenitors into myeloid 
cells. Thus, TLR ligands are effective regulators of extra-
medullary hematopoiesis.37 This suggests that infection may 
significantly affect the hematopoiesis in the marrow and 
peripheral organs, such as the spleen.
The function of TLR ligands in regulation of hemato-
poiesis suggests that infection is an important element for 
EH to occur. As an example, it has been determined that 
Leishmania major infection increases colony-forming unit 
cells or myeloid progenitors in the spleen.38 Interestingly, the 
response in BALB/c mice was greater than that in C57BL/6 
mice. This could be due to the lesser ability of BALB/c mice 
to clear the infection by intracellular pathogens. One of the 
mechanisms for the increased myelopoietic activity appears 
to be the production of GM-CSF and TNF-α,39 which can 
synergistically support the growth and maturation of myeloid 
progenitors.Journal of Blood Medicine 2010:1 17
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Infection with Plasmodium berghei (ie, malaria) provided 
more insights into the kinetics of hematopoietic shift from the 
bone marrow to spleen.40 Infection with Plasmodium berghei 
increased numbers of CFU-GM in the bone marrow during 
the first week of infection, which was followed by a rise of 
CFU-GM in the peripheral blood and finally in the spleen 
around the end of the second week. The marrow progenitor 
numbers were normalized within two weeks, but those of the 
spleen remained elevated for a more prolonged time period. 
It is unclear how the hematopoiesis in the marrow and the 
spleen is sequentially regulated.
EH in an infection would generate sufficient numbers 
of mature myeloid cells to help clear pathogens, however, 
increased myelopoiesis without proper maturation of the 
myeloid progenitors could induce CD11b+ GR-1+ myeloid-
derived suppressor cells.41,42 Myeloid-derived suppressor 
cells emerge in the spleen and other organs impacted by 
infection and cancer. These cells are highly heterogeneous 
and are considered normal constituents of myelopoiesis.41 
Thus, incomplete EH could ultimately hamper immune 
responses to pathogens.
EH as the result of chronic  
myeloproliferative syndrome
Extramedullary hematopoiesis occurs if the bone marrow 
is no longer functional. Primary myelofibrosis is a form 
of Philadelphia-negative chronic myeloproliferative syn-
drome.43 In primary myelofibrosis, displacement and mobili-
zation of stem and progenitor cells occur. As a consequence, 
hematopoietic stem and progenitor cells occupy the liver and 
spleen as alternative sites of hematopoiesis. At the same time, 
the bone marrow stem cell niche is altered so that it no longer 
supports normal hematopoiesis.44–46 Thus, in primary myelo-
fibrosis, the site of hematopoiesis changes from the marrow 
to the spleen and liver. Primary myelofibrosis and related 
Philadelphia-negative chronic myeloproliferative syndrome 
are associated with a point mutation in the tyrosine kinase 
JAK2 (JAK2V617F).47–50 It is thought that this mutation 
makes hematopoietic stem and progenitor cells more sensi-
tive to growth factors, alters the marrow stem cell niche, and 
causes the cells to mobilize to the spleen and liver. Another 
notable feature of primary myelofibrosis is the high produc-
tion of inflammatory cytokines such as SDF-1, HGF, IL-6, 
IL-8, SCF, and VEGF. Likewise, the factors that promote 
fibrosis and angiogenesis (bFGF, TGF-β, PF4, VEGF, etc) 
are increased.51–53 These molecules are produced mainly by 
hematopoietic cells and contribute to the regulatory humoral 
changes occurring within the medullar and spleen niches. 
In addition to the JAK2 mutation, activating mutations 
affecting the thrombopoietin receptor MPL (MPLW515L 
and MPLW515K) have been found in small numbers of 
patients with Philadelphia-negative chronic myeloprolifera-
tive syndrome.54,55 EH, particularly EH in myelofibrosis, can 
never fully replace the marrow hematopoiesis in production 
of necessary blood cells, however.
Conclusion
While the bone marrow is the major site of hematopoiesis, it 
can occur in many other tissues both during fetal development 
and after birth. Extramedullary hematopoiesis can occur as 
long as there are appropriate supporting cells, accommoda-
tion of hematopoietic progenitors, and local production of 
soluble and cell-bound hematopoietic factors that maintain 
and induce differentiation of the stem and progenitor cells. 
Extramedullary hematopoiesis occurs under several condi-
tions, both actively and passively. It plays an essential role 
during fetal development, namely the survival of the fetus 
before formation of the functional marrow hematopoietic 
niche. As a normal response to infection and inflamma-
tion, myelopoiesis occurs in the spleen and liver to produce 
phagocytic cells and antigen-presenting cells. In malignant 
conditions, such as various forms of myelofibrosis, the mar-
row hematopoietic niche becomes inhabitable, and hemato-
poietic stem and progenitor cells move out to the periphery. 
EH cannot fully supplant the marrow hematopoiesis in terms 
of the production of necessary hematopoietic cells, rather 
it is imperative for the maturation of hematopoietic cells 
which are produced as immature cells in the marrow. While 
programmed extramedullary hematopoiesis is required to 
supplement the hematopoietic activity in the bone marrow, 
excessive and disease-associated extramedullary hemato-
poiesis can occur and mediate chronic inflammation. More 
research is required to discover useful strategies for control-
ling unwanted extramedullary hematopoiesis and chronic 
inflammation.
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